BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37552362)

  • 21. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
    Armocida D; Pesce A; Frati A; Santoro A; Salvati M
    J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
    Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.
    Sartori E; Langer R; Vassella E; Hewer E; Schucht P; Zlobec I; Berezowska S
    Oncol Rep; 2017 Oct; 38(4):2394-2400. PubMed ID: 28765916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
    Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDH
    Wang S; Li L; Zuo S; Kong L; Wei J; Dong J
    Front Immunol; 2022; 13():869061. PubMed ID: 36248907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
    Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of STAT3 gene expression in patients with glioblastoma tumors: a study from Western India.
    Trivedi T; Panchal K; Bhalala N; Trivedi P
    J Egypt Natl Canc Inst; 2022 Jul; 34(1):30. PubMed ID: 35844028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
    Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
    JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
    BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
    Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
    Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
    Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
    Front Oncol; 2019; 9():1433. PubMed ID: 31921684
    [No Abstract]   [Full Text] [Related]  

  • 35. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptional diversity of long-term glioblastoma survivors.
    Gerber NK; Goenka A; Turcan S; Reyngold M; Makarov V; Kannan K; Beal K; Omuro A; Yamada Y; Gutin P; Brennan CW; Huse JT; Chan TA
    Neuro Oncol; 2014 Sep; 16(9):1186-95. PubMed ID: 24662514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the Prognosis of High-Grade gliomas in the View of New Immunohistochemistry Markers and 2016 WHO Classification.
    Dolen D; Ahmadov T; Dolas I; Unal TC; Aydoseli A; Ozturk M; Sabanci PA; Aras Y; Bilgic MB; Sencer A
    Turk Neurosurg; 2022; 32(3):500-507. PubMed ID: 35615769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.
    Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK
    Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.